{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T11:16:03Z","timestamp":1783163763794,"version":"3.54.6"},"reference-count":171,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100007046","name":"Wuhan University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007046","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","translationalres.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Translational Research"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.trsl.2026.05.004","type":"journal-article","created":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T15:17:54Z","timestamp":1779290274000},"page":"29-43","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Targeted protein degradation in inflammatory bone diseases: Mechanistic basis and therapeutic opportunities"],"prefix":"10.1016","volume":"293","author":[{"given":"Yu-Xuan","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan-Hao","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiu-Hui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9049-8807","authenticated-orcid":false,"given":"Lu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.trsl.2026.05.004_bib0001","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.3390\/ijms23031786","article-title":"Interplay between inflammation and pathological bone resorption: insights into recent mechanisms and pathways in related diseases for future perspectives","volume":"23","author":"Terkawi","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/j.trsl.2026.05.004_bib0002","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1007\/s12016-015-8523-6","article-title":"Non-canonical (RANKL-Independent) pathways of osteoclast differentiation and their role in musculoskeletal diseases","volume":"51","author":"Sabokbar","year":"2016","journal-title":"Clin Rev Allergy Immunol"},{"issue":"6","key":"10.1016\/j.trsl.2026.05.004_bib0003","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1007\/s11914-023-00824-4","article-title":"Inflammatory processes affecting bone health and repair","volume":"21","author":"Torres","year":"2023","journal-title":"Curr Osteoporos Rep"},{"issue":"13","key":"10.1016\/j.trsl.2026.05.004_bib0004","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1001\/jama.2018.13103","article-title":"Diagnosis and management of rheumatoid arthritis: a review","volume":"320","author":"Aletaha","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.trsl.2026.05.004_bib0005","doi-asserted-by":"crossref","first-page":"n2321","DOI":"10.1136\/bmj.n2321","article-title":"Effectiveness and safety of non-steroidal anti-inflammatory drugs and opioid treatment for knee and hip osteoarthritis: network meta-analysis","volume":"375","author":"da Costa","year":"2021","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.trsl.2026.05.004_bib0006","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1093\/oxfordjournals.rheumatology.a031492","article-title":"Current treatment paradigms in rheumatoid arthritis","volume":"39","author":"Fries","year":"2000","journal-title":"Rheumatol"},{"issue":"4","key":"10.1016\/j.trsl.2026.05.004_bib0007","doi-asserted-by":"crossref","first-page":"880","DOI":"10.3390\/cells9040880","article-title":"Update on the pathomechanism, diagnosis, and treatment options for rheumatoid arthritis","volume":"9","author":"Lin","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.trsl.2026.05.004_bib0008","doi-asserted-by":"crossref","unstructured":"Okamoto K., T.H. Osteoimmunology. Cold Spring Harb Perspect Med. 2019;9(1):a031245. doi:10.1101\/cshperspect.a031245.","DOI":"10.1101\/cshperspect.a031245"},{"key":"10.1016\/j.trsl.2026.05.004_bib0009","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.800508","article-title":"Editorial: recent advances in basic and translational osteoimmunology","volume":"12","author":"Srivastava","year":"2021","journal-title":"Front Immunol"},{"issue":"7","key":"10.1016\/j.trsl.2026.05.004_bib0010","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1038\/s41419-021-03939-7","article-title":"A novel BRD4 inhibitor suppresses osteoclastogenesis and ovariectomized osteoporosis by blocking RANKL-mediated MAPK and NF-\u03bab pathways","volume":"12","author":"Liu","year":"2021","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.trsl.2026.05.004_bib0011","article-title":"Targeting STING: from antiviral immunity to treat osteoporosis","volume":"13","author":"Gao","year":"2022","journal-title":"Front Immunol"},{"issue":"9","key":"10.1016\/j.trsl.2026.05.004_bib0012","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1038\/s41580-024-00729-9","article-title":"Targeted protein degradation: from mechanisms to clinic","volume":"25","author":"Tsai","year":"2024","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"3","key":"10.1016\/j.trsl.2026.05.004_bib0013","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/s41573-021-00371-6","article-title":"PROTAC targeted protein degraders: the past is prologue","volume":"21","author":"B\u00e9k\u00e9s","year":"2022","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.trsl.2026.05.004_bib0014","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2021.100647","article-title":"Major advances in targeted protein degradation: pROTACs, LYTACs, and MADTACs","volume":"296","author":"Alabi","year":"2021","journal-title":"J Biol Chem"},{"issue":"12","key":"10.1016\/j.trsl.2026.05.004_bib0015","article-title":"Tailoring biomaterials ameliorate inflammatory bone loss","volume":"13","author":"Cheng","year":"2024","journal-title":"Adv Heal Mater"},{"issue":"3","key":"10.1016\/j.trsl.2026.05.004_bib0016","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/nrd3669","article-title":"Inflammatory bone loss: pathogenesis and therapeutic intervention","volume":"11","author":"Redlich","year":"2012","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"10.1016\/j.trsl.2026.05.004_bib0017","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.joca.2012.11.012","article-title":"Osteoarthritis as an inflammatory disease (osteoarthritis is not osteoarthrosis!)","volume":"21","author":"Berenbaum","year":"2013","journal-title":"Osteoarthr Cartil"},{"issue":"2","key":"10.1016\/j.trsl.2026.05.004_bib0018","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s11914-012-0104-5","article-title":"Pathways for bone loss in inflammatory disease","volume":"10","author":"Braun","year":"2012","journal-title":"Curr Osteoporos Rep"},{"issue":"1","key":"10.1016\/j.trsl.2026.05.004_bib0019","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.ejphar.2008.04.024","article-title":"Paeonol inhibits RANKL-induced osteoclastogenesis by inhibiting ERK, p38 and NF-kappaB pathway","volume":"588","author":"Tsai","year":"2008","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.trsl.2026.05.004_bib0020","doi-asserted-by":"crossref","first-page":"507","DOI":"10.3389\/fcell.2020.00507","article-title":"Osteoclast signal transduction during bone metastasis formation","volume":"8","author":"Gy\u0151ri","year":"2020","journal-title":"Front Cell Dev Biol"},{"issue":"1","key":"10.1016\/j.trsl.2026.05.004_bib0021","doi-asserted-by":"crossref","DOI":"10.4110\/in.2018.18.e8","article-title":"Regulation of osteoclast differentiation by Cytokine Networks","volume":"18","author":"Amarasekara","year":"2018","journal-title":"Immune Netw"},{"issue":"3","key":"10.1016\/j.trsl.2026.05.004_bib0022","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.3390\/ijms23031376","article-title":"Osteoporosis due to hormone imbalance: an overview of the effects of estrogen deficiency and glucocorticoid overuse on bone turnover","volume":"23","author":"Cheng","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"3","key":"10.1016\/j.trsl.2026.05.004_bib0023","doi-asserted-by":"crossref","first-page":"544","DOI":"10.3803\/EnM.2021.301","article-title":"Long-term treatment of postmenopausal osteoporosis","volume":"36","author":"Brown","year":"2021","journal-title":"Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.trsl.2026.05.004_bib0024","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2020.102741","article-title":"An overview of the NF-\u03bab mechanism of pathophysiology in rheumatoid arthritis, investigation of the NF-\u03bab ligand RANKL and related nutritional interventions","volume":"20","author":"Ilchovska","year":"2021","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.trsl.2026.05.004_bib0025","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2015\/615486","article-title":"Mechanisms of bone resorption in periodontitis","volume":"2015","author":"Hienz","year":"2015","journal-title":"J Immunol Res"},{"issue":"2","key":"10.1016\/j.trsl.2026.05.004_bib0026","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.imlet.2015.05.016","article-title":"Targeting bromodomain-containing protein 4 (BRD4) benefits rheumatoid arthritis","volume":"166","author":"Zhang","year":"2015","journal-title":"Immunol Lett"},{"issue":"3","key":"10.1016\/j.trsl.2026.05.004_bib0027","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1007\/s11010-024-05073-2","article-title":"Targeting BRD4 to attenuate RANKL-induced osteoclast activation and bone erosion in rheumatoid arthritis","volume":"480","author":"Wang","year":"2025","journal-title":"Mol Cell Biochem"},{"issue":"1","key":"10.1016\/j.trsl.2026.05.004_bib0028","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/s41419-020-03341-9","article-title":"STING promotes senescence, apoptosis, and extracellular matrix degradation in osteoarthritis via the NF-\u03bab signaling pathway","volume":"12","author":"Guo","year":"2021","journal-title":"Cell Death Dis"},{"issue":"12","key":"10.1016\/j.trsl.2026.05.004_bib0029","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1177\/15353702221087966","article-title":"Identification in synovial fluid of a new potential pathogenic player in arthropathies","volume":"247","author":"Scanu","year":"2022","journal-title":"Exp Biol Med (Maywood)"},{"key":"10.1016\/j.trsl.2026.05.004_bib0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2024.111588","article-title":"Astragaloside IV alleviates macrophage senescence and D-galactose-induced bone loss in mice through STING\/NF-\u03bab pathway","volume":"129","author":"Li","year":"2024","journal-title":"Int Immunopharmacol"},{"issue":"4","key":"10.1016\/j.trsl.2026.05.004_bib0031","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/s00281-017-0623-3","article-title":"Future therapeutic targets in rheumatoid arthritis?","volume":"39","author":"Cheung","year":"2017","journal-title":"Semin Immunopathol"},{"issue":"1","key":"10.1016\/j.trsl.2026.05.004_bib0032","doi-asserted-by":"crossref","DOI":"10.1111\/cbdd.14582","article-title":"Therapeutic potential and recent progression of BTK inhibitors against rheumatoid arthritis","volume":"104","author":"Paliwal","year":"2024","journal-title":"Chem Biol Drug Des"},{"issue":"7","key":"10.1016\/j.trsl.2026.05.004_bib0033","doi-asserted-by":"crossref","first-page":"3073","DOI":"10.1016\/j.apsb.2022.02.010","article-title":"Targeting macrophagic SHP2 for ameliorating osteoarthritis via TLR signaling","volume":"12","author":"Sun","year":"2022","journal-title":"Acta Pharm Sin B"},{"issue":"1","key":"10.1016\/j.trsl.2026.05.004_bib0034","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41413-020-00129-7","article-title":"Targeted Ptpn11 deletion in mice reveals the essential role of SHP2 in osteoblast differentiation and skeletal homeostasis","volume":"9","author":"Wang","year":"2021","journal-title":"Bone Res"},{"issue":"7","key":"10.1016\/j.trsl.2026.05.004_bib0035","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.86580","article-title":"Abnormal PTPN11 enhancer methylation promotes rheumatoid arthritis fibroblast-like synoviocyte aggressiveness and joint inflammation","volume":"1","author":"Maeshima","year":"2016","journal-title":"JCI Insight"},{"issue":"17","key":"10.1016\/j.trsl.2026.05.004_bib0036","doi-asserted-by":"crossref","first-page":"12263","DOI":"10.18632\/aging.206084","article-title":"Excessive glucocorticoids combined with RANKL promote the differentiation of bone marrow macrophages (BMM) into osteoclasts and accelerate the progression of osteoporosis by activating the SYK\/SHP2\/NF-\u03bab signaling pathway","volume":"16","author":"Dong","year":"2024","journal-title":"Aging"},{"issue":"4","key":"10.1016\/j.trsl.2026.05.004_bib0037","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.immuni.2008.07.018","article-title":"Interleukin-17 promotes autoimmunity by triggering a positive-feedback loop via interleukin-6 induction","volume":"29","author":"Ogura","year":"2008","journal-title":"Immunity"},{"issue":"23","key":"10.1016\/j.trsl.2026.05.004_bib0038","doi-asserted-by":"crossref","first-page":"9004","DOI":"10.3390\/ijms21239004","article-title":"JAK\/STAT activation: a general mechanism for bone development, homeostasis, and regeneration","volume":"21","author":"Damerau","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.trsl.2026.05.004_bib0039","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.jare.2024.07.031","article-title":"NAT10 promotes osteoclastogenesis in inflammatory bone loss by catalyzing Fos mRNA ac4C modification and upregulating MAPK signaling pathway","volume":"72","author":"Yang","year":"2025","journal-title":"J Adv Res"},{"issue":"1","key":"10.1016\/j.trsl.2026.05.004_bib0040","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1038\/s41392-024-02004-x","article-title":"Targeted protein degradation: advances in drug discovery and clinical practice","volume":"9","author":"Zhong","year":"2024","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"10.1016\/j.trsl.2026.05.004_bib0041","first-page":"1","article-title":"Relationship between the proteasomal system and autophagy","volume":"4","author":"Lilienbaum","year":"2013","journal-title":"Int J Biochem Mol Biol"},{"issue":"15","key":"10.1016\/j.trsl.2026.05.004_bib0042","article-title":"Aptamer-LYTACs for targeted degradation of extracellular and membrane proteins","volume":"62","author":"Wu","year":"2023","journal-title":"Angew Chem Int Engl"},{"issue":"8","key":"10.1016\/j.trsl.2026.05.004_bib0043","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1021\/acs.bioconjchem.4c00253","article-title":"Targeted protein degradation (TPD) for immunotherapy: understanding proteolysis targeting chimera-driven ubiquitin-proteasome interactions","volume":"35","author":"Kamaraj","year":"2024","journal-title":"Bioconjug Chem"},{"issue":"1","key":"10.1016\/j.trsl.2026.05.004_bib0044","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s13045-020-00885-3","article-title":"Proteolysis-targeting chimera (PROTAC) for targeted protein degradation and cancer therapy","volume":"13","author":"Li","year":"2020","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.trsl.2026.05.004_bib0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112981","article-title":"Proteolysis targeting chimera (PROTAC) in drug discovery paradigm: recent progress and future challenges","volume":"210","author":"Zeng","year":"2021","journal-title":"Eur J Med Chem"},{"issue":"7820","key":"10.1016\/j.trsl.2026.05.004_bib0046","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1038\/s41586-020-2545-9","article-title":"Lysosome-targeting chimaeras for degradation of extracellular proteins","volume":"584","author":"Banik","year":"2020","journal-title":"Nature"},{"issue":"9","key":"10.1016\/j.trsl.2026.05.004_bib0047","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1038\/s41589-021-00770-1","article-title":"LYTACs that engage the asialoglycoprotein receptor for targeted protein degradation","volume":"17","author":"Ahn","year":"2021","journal-title":"Nat Chem Biol"},{"issue":"11","key":"10.1016\/j.trsl.2026.05.004_bib0048","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1016\/j.scib.2024.03.056","article-title":"Targeting the undruggables-the power of protein degraders","volume":"69","author":"Zhang","year":"2024","journal-title":"Sci Bull"},{"issue":"5","key":"10.1016\/j.trsl.2026.05.004_bib0049","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/j.molcel.2019.09.009","article-title":"AUTACs: cargo-specific degraders using selective autophagy","volume":"76","author":"Takahashi","year":"2019","journal-title":"Mol Cell"},{"issue":"1","key":"10.1016\/j.trsl.2026.05.004_bib0050","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1080\/15548627.2019.1688556","article-title":"ATTEC: a potential new approach to target proteinopathies","volume":"16","author":"Li","year":"2020","journal-title":"Autophagy"},{"issue":"23","key":"10.1016\/j.trsl.2026.05.004_bib0051","doi-asserted-by":"crossref","first-page":"3013","DOI":"10.1016\/j.scib.2023.10.021","article-title":"Targeted clearance of mitochondria by an autophagy-tethering compound (ATTEC) and its potential therapeutic effects","volume":"68","author":"Tan","year":"2023","journal-title":"Sci Bull"},{"issue":"3","key":"10.1016\/j.trsl.2026.05.004_bib0052","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.xphs.2023.10.023","article-title":"Targeted protein degraders- the druggability perspective","volume":"113","author":"Singh","year":"2024","journal-title":"J Pharm Sci"},{"issue":"3","key":"10.1016\/j.trsl.2026.05.004_bib0053","doi-asserted-by":"crossref","first-page":"119","DOI":"10.4155\/fmc-2021-0223","article-title":"Challenges and opportunities for in vivo PROTAC delivery","volume":"14","author":"Benowitz","year":"2022","journal-title":"Future Med Chem"},{"issue":"17","key":"10.1016\/j.trsl.2026.05.004_bib0054","doi-asserted-by":"crossref","first-page":"12978","DOI":"10.1021\/acs.jmedchem.1c01118","article-title":"Optimization of a series of RIPK2 PROTACs","volume":"64","author":"Miah","year":"2021","journal-title":"J Med Chem"},{"key":"10.1016\/j.trsl.2026.05.004_bib0055","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.jconrel.2022.05.045","article-title":"Dissolving microneedles: applications and growing therapeutic potential","volume":"348","author":"Sartawi","year":"2022","journal-title":"J Control Release"},{"issue":"12","key":"10.1016\/j.trsl.2026.05.004_bib0056","doi-asserted-by":"crossref","first-page":"10336","DOI":"10.1021\/acs.jmedchem.4c00828","article-title":"A top-down design approach for generating a peptide PROTAC drug targeting androgen receptor for androgenetic alopecia therapy","volume":"67","author":"Ma","year":"2024","journal-title":"J Med Chem"},{"issue":"13","key":"10.1016\/j.trsl.2026.05.004_bib0057","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202411869","article-title":"Self-oxygenating PROTAC microneedle for spatiotemporally-confined protein degradation and enhanced glioblastoma therapy","volume":"37","author":"Jiang","year":"2025","journal-title":"Adv Mater"},{"issue":"1","key":"10.1016\/j.trsl.2026.05.004_bib0058","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/s41587-021-01173-2","article-title":"The PROTAC gold rush","volume":"40","author":"Garber","year":"2022","journal-title":"Nat Biotechnol"},{"issue":"8","key":"10.1016\/j.trsl.2026.05.004_bib0059","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1038\/s41401-024-01266-z","article-title":"Tumor-targeted PROTAC prodrug nanoplatform enables precise protein degradation and combination cancer therapy","volume":"45","author":"Zou","year":"2024","journal-title":"Acta Pharmacol Sin"},{"issue":"1","key":"10.1016\/j.trsl.2026.05.004_bib0060","doi-asserted-by":"crossref","first-page":"6509","DOI":"10.1038\/s41467-023-42233-2","article-title":"Expanding PROTACtable genome universe of E3 ligases","volume":"14","author":"Liu","year":"2023","journal-title":"Nat Commun"},{"issue":"72","key":"10.1016\/j.trsl.2026.05.004_bib0061","doi-asserted-by":"crossref","first-page":"10072","DOI":"10.1039\/D2CC03367D","article-title":"Reactive oxygen species-responsive pre-PROTAC for tumor-specific protein degradation","volume":"58","author":"Liu","year":"2022","journal-title":"Chem Commun"},{"issue":"1","key":"10.1016\/j.trsl.2026.05.004_bib0062","doi-asserted-by":"crossref","first-page":"6608","DOI":"10.1038\/s41467-024-50735-w","article-title":"A region-confined PROTAC nanoplatform for spatiotemporally tunable protein degradation and enhanced cancer therapy","volume":"15","author":"Gao","year":"2024","journal-title":"Nat Commun"},{"issue":"28","key":"10.1016\/j.trsl.2026.05.004_bib0063","doi-asserted-by":"crossref","first-page":"8741","DOI":"10.1021\/acs.nanolett.4c02287","article-title":"Ultrasound-activated PROTAC prodrugs overcome immunosuppression to actuate efficient deep-tissue sono-immunotherapy in orthotopic pancreatic tumor mouse models","volume":"24","author":"Liu","year":"2024","journal-title":"Nano Lett"},{"issue":"14","key":"10.1016\/j.trsl.2026.05.004_bib0064","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1002\/cmdc.202000249","article-title":"Controlling PROTACs with light","volume":"15","author":"Verma","year":"2020","journal-title":"ChemMedChem"},{"issue":"7","key":"10.1016\/j.trsl.2026.05.004_bib0065","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/j.chembiol.2021.05.010","article-title":"Optical control of targeted protein degradation","volume":"28","author":"Reynders","year":"2021","journal-title":"Cell Chem Biol"},{"issue":"46","key":"10.1016\/j.trsl.2026.05.004_bib0066","doi-asserted-by":"crossref","first-page":"18370","DOI":"10.1021\/jacs.9b06422","article-title":"Light-induced protein degradation with photocaged PROTACs","volume":"141","author":"Xue","year":"2019","journal-title":"J Am Chem Soc"},{"issue":"10","key":"10.1016\/j.trsl.2026.05.004_bib0067","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1021\/acscentsci.9b00713","article-title":"Reversible spatiotemporal control of induced protein degradation by bistable PhotoPROTACs","volume":"5","author":"Pfaff","year":"2019","journal-title":"ACS Cent Sci"},{"issue":"12","key":"10.1016\/j.trsl.2026.05.004_bib0068","article-title":"Photoswitchable PROTACs for reversible and spatiotemporal regulation of NAMPT and NAD","volume":"63","author":"Cheng","year":"2024","journal-title":"Angew Chem Int Engl"},{"key":"10.1016\/j.trsl.2026.05.004_bib0069","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2023.106497","article-title":"Discovery of novel protein degraders based on bioorthogonal reaction-driven intracellular self-assembly strategy","volume":"135","author":"Si","year":"2023","journal-title":"Bioorg Chem"},{"key":"10.1016\/j.trsl.2026.05.004_bib0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115497","article-title":"Discovery of intracellular self-assembly protein degraders driven by tumor-specific activatable bioorthogonal reaction","volume":"257","author":"Si","year":"2023","journal-title":"Eur J Med Chem"},{"issue":"23","key":"10.1016\/j.trsl.2026.05.004_bib0071","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202500311","article-title":"A self-assembling LYTAC mediates CTGF degradation and remodels inflammatory tumor microenvironment for triple-negative breast cancer therapy","volume":"12","author":"Lin","year":"2025","journal-title":"Adv Sci"},{"issue":"5","key":"10.1016\/j.trsl.2026.05.004_bib0072","article-title":"Self-assembled peptide-derived proteolysis-targeting Chimera (PROTAC) nanoparticles for tumor-targeted and durable PD-L1 degradation in cancer immunotherapy","volume":"64","author":"Moon","year":"2025","journal-title":"Angew Chem Int Engl"},{"issue":"37","key":"10.1016\/j.trsl.2026.05.004_bib0073","article-title":"Nano proteolysis targeting chimeras (PROTACs) with anti-hook effect for tumor therapy","volume":"62","author":"Zhang","year":"2023","journal-title":"Angew Chem Int Engl"},{"issue":"8","key":"10.1016\/j.trsl.2026.05.004_bib0074","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1021\/acs.accounts.5c00003","article-title":"Strategies for precise modulation of protein degradation","volume":"58","author":"He","year":"2025","journal-title":"Acc Chem Res"},{"issue":"43","key":"10.1016\/j.trsl.2026.05.004_bib0075","doi-asserted-by":"crossref","first-page":"23299","DOI":"10.1002\/anie.202107347","article-title":"Aptamer-PROTAC conjugates (APCs) for tumor-specific targeting in breast cancer","volume":"60","author":"He","year":"2021","journal-title":"Angew Chem Int Engl"},{"issue":"26","key":"10.1016\/j.trsl.2026.05.004_bib0076","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202309639","article-title":"Antitumor effect of Anti-c-myc aptamer-based PROTAC for degradation of the c-myc protein","volume":"11","author":"Wang","year":"2024","journal-title":"Adv Sci"},{"issue":"16","key":"10.1016\/j.trsl.2026.05.004_bib0077","doi-asserted-by":"crossref","first-page":"9334","DOI":"10.1021\/jacs.3c02619","article-title":"c-myc-targeting PROTAC based on a TNA-DNA bivalent binder for combination therapy of triple-negative breast cancer","volume":"145","author":"Li","year":"2023","journal-title":"J Am Chem Soc"},{"issue":"13","key":"10.1016\/j.trsl.2026.05.004_bib0078","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1016\/j.scib.2024.05.017","article-title":"An engineered DNA aptamer-based PROTAC for precise therapy of p53-R175H hotspot mutant-driven cancer","volume":"69","author":"Kong","year":"2024","journal-title":"Sci Bull"},{"issue":"6","key":"10.1016\/j.trsl.2026.05.004_bib0079","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2025.104376","article-title":"Voisin-Chiret AS. PROTAC 2.0: expanding the frontiers of targeted protein degradation","volume":"30","author":"Cornu","year":"2025","journal-title":"Drug Discov Today"},{"issue":"1","key":"10.1016\/j.trsl.2026.05.004_bib0080","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/cmdc.201900497","article-title":"Antibody conjugation of a chimeric BET degrader enables invivo activity","volume":"15","author":"Pillow","year":"2020","journal-title":"ChemMedChem"},{"issue":"22","key":"10.1016\/j.trsl.2026.05.004_bib0081","doi-asserted-by":"crossref","first-page":"10141","DOI":"10.7150\/thno.46985","article-title":"The peptide PROTAC modality: a novel strategy for targeted protein ubiquitination","volume":"10","author":"Jin","year":"2020","journal-title":"Theranostics"},{"issue":"1","key":"10.1016\/j.trsl.2026.05.004_bib0082","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/s41589-022-01218-w","article-title":"Targeted degradation via direct 26S proteasome recruitment","volume":"19","author":"Bashore","year":"2023","journal-title":"Nat Chem Biol"},{"issue":"11","key":"10.1016\/j.trsl.2026.05.004_bib0083","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.1021\/acschembio.4c00422","article-title":"Recruitment to the proteasome is necessary but not sufficient for chemically induced, ubiquitin-independent degradation of native proteins","volume":"19","author":"Balzarini","year":"2024","journal-title":"ACS Chem Biol"},{"key":"10.1016\/j.trsl.2026.05.004_bib0084","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115741","article-title":"Hydrophobic tag-based protein degradation: development, opportunity and challenge","volume":"260","author":"He","year":"2023","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.trsl.2026.05.004_bib0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2025.108184","article-title":"AT1, a small molecular degrader of BRD4 based on proteolysis targeting chimera technology alleviates renal fibrosis and inflammation in diabetic nephropathy","volume":"156","author":"Yang","year":"2025","journal-title":"Bioorg Chem"},{"issue":"1","key":"10.1016\/j.trsl.2026.05.004_bib0086","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1186\/s12974-022-02533-8","article-title":"Targeted BRD4 protein degradation by dBET1 ameliorates acute ischemic brain injury and improves functional outcomes associated with reduced neuroinflammation and oxidative stress and preservation of blood-brain barrier integrity","volume":"19","author":"Liu","year":"2022","journal-title":"J Neuroinflammation"},{"key":"10.1016\/j.trsl.2026.05.004_bib0087","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2024.112646","article-title":"A novel PROTAC molecule dBET1 alleviates pathogenesis of experimental autoimmune encephalomyelitis in mice by degrading BRD4","volume":"139","author":"Song","year":"2024","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.trsl.2026.05.004_bib0088","article-title":"Cartilage targeting hydrogel nanoplatform degrades BRD4 to alleviate osteoarthritis via Nav1.7 axis","author":"Zhao","year":"2026","journal-title":"Nat Commun"},{"key":"10.1016\/j.trsl.2026.05.004_bib0089","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.jconrel.2024.10.007","article-title":"Targeted nanoliposomes of oncogenic protein degraders: significant inhibition of tumor in lung-cancer bearing mice","volume":"376","author":"Vartak","year":"2024","journal-title":"J Control Release"},{"issue":"5","key":"10.1016\/j.trsl.2026.05.004_bib0090","doi-asserted-by":"crossref","first-page":"4547","DOI":"10.18632\/aging.102910","article-title":"ARV-825-induced BRD4 protein degradation as a therapy for thyroid carcinoma","volume":"12","author":"He","year":"2020","journal-title":"Aging"},{"key":"10.1016\/j.trsl.2026.05.004_bib0091","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2024.111991","article-title":"Targeting BRD4 with PROTAC degrader ameliorates LPS-induced acute lung injury by inhibiting M1 alveolar macrophage polarization","volume":"132","author":"Li","year":"2024","journal-title":"Int Immunopharmacol"},{"issue":"1","key":"10.1016\/j.trsl.2026.05.004_bib0092","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s12931-025-03120-0","article-title":"Targeting BRD4 ameliorates experimental emphysema by disrupting super-enhancer in polarized alveolar macrophage","volume":"26","author":"Li","year":"2025","journal-title":"Respir Res"},{"issue":"8002","key":"10.1016\/j.trsl.2026.05.004_bib0093","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/s41586-024-07089-6","article-title":"Targeted protein degradation via intramolecular bivalent glues","volume":"627","author":"Hsia","year":"2024","journal-title":"Nature"},{"issue":"13","key":"10.1016\/j.trsl.2026.05.004_bib0094","doi-asserted-by":"crossref","first-page":"3328","DOI":"10.3390\/ijms20133328","article-title":"The NLRP3 inflammasome: an overview of mechanisms of activation and regulation","volume":"20","author":"Kelley","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.trsl.2026.05.004_bib0095","doi-asserted-by":"crossref","first-page":"262","DOI":"10.3389\/fphar.2015.00262","article-title":"NLRP3 inflammasome and its inhibitors: a review","volume":"6","author":"Shao","year":"2015","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.trsl.2026.05.004_bib0096","doi-asserted-by":"crossref","DOI":"10.1016\/j.jep.2020.113447","article-title":"Morroniside attenuates apoptosis and pyroptosis of chondrocytes and ameliorates osteoarthritic development by inhibiting NF-\u03bab signaling","volume":"266","author":"Yu","year":"2021","journal-title":"J Ethnopharmacol"},{"issue":"2","key":"10.1016\/j.trsl.2026.05.004_bib0097","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1111\/cei.13167","article-title":"NLRP3 inflammasome activation contributes to the pathogenesis of rheumatoid arthritis","volume":"194","author":"Guo","year":"2018","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.trsl.2026.05.004_bib0098","article-title":"NLRP3 Inflammasome: checkpoint connecting innate and adaptive immunity in autoimmune diseases","volume":"12","author":"Zhang","year":"2021","journal-title":"Front Immunol"},{"issue":"6","key":"10.1016\/j.trsl.2026.05.004_bib0099","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.jbiosc.2021.02.007","article-title":"Exosomes from adipose derived mesenchymal stem cells alleviate diabetic osteoporosis in rats through suppressing NLRP3 inflammasome activation in osteoclasts","volume":"131","author":"Zhang","year":"2021","journal-title":"J Biosci Bioeng"},{"key":"10.1016\/j.trsl.2026.05.004_bib0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2021.107901","article-title":"HIF-1\u03b1 activator DMOG inhibits alveolar bone resorption in murine periodontitis by regulating macrophage polarization","volume":"99","author":"Chen","year":"2021","journal-title":"Int Immunopharmacol"},{"issue":"5","key":"10.1016\/j.trsl.2026.05.004_bib0101","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1177\/0022034520910127","article-title":"Akt2 Affects periodontal inflammation via altering the M1\/M2 ratio","volume":"99","author":"Wu","year":"2020","journal-title":"J Dent Res"},{"issue":"6","key":"10.1016\/j.trsl.2026.05.004_bib0102","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1016\/j.archoralbio.2015.03.005","article-title":"The expression of NLRP3, NLRP1 and AIM2 in the gingival tissue of periodontitis patients: RT-PCR study and immunohistochemistry","volume":"60","author":"Xue","year":"2015","journal-title":"Arch Oral Biol"},{"key":"10.1016\/j.trsl.2026.05.004_bib0103","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2024.112990","article-title":"PROTAC based STING degrader attenuates acute colitis by inhibiting macrophage M1 polarization and intestinal epithelial cells pyroptosis mediated by STING-NLRP3 axis","volume":"141","author":"Xu","year":"2024","journal-title":"Int Immunopharmacol"},{"issue":"12","key":"10.1016\/j.trsl.2026.05.004_bib0104","article-title":"Selective and potent molecular glue degraders for NIMA-related kinase 7","volume":"64","author":"Chen","year":"2025","journal-title":"Angew Chem Int Engl"},{"issue":"14","key":"10.1016\/j.trsl.2026.05.004_bib0105","doi-asserted-by":"crossref","first-page":"3001","DOI":"10.1039\/D4CC06321J","article-title":"Degrading the key component of the inflammasome: development of an NLRP3 PROTAC","volume":"61","author":"Keuler","year":"2025","journal-title":"Chem Commun (Camb)"},{"key":"10.1016\/j.trsl.2026.05.004_bib0106","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116581","article-title":"Discovery of autophagy-tethering compounds as potent NLRP3 degraders for IBD Immunotherapy","volume":"275","author":"Yin","year":"2024","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.trsl.2026.05.004_bib0107","article-title":"Revisiting osteoarthritis pathogenesis through the lens of cGAS-STING: mitochondrial damage, pyroptosis, and inflammatory cascades","volume":"56","author":"Hu","year":"2026","journal-title":"J Orthop Transl"},{"key":"10.1016\/j.trsl.2026.05.004_bib0108","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.freeradbiomed.2024.09.031","article-title":"STING regulates aging-related osteoporosis by mediating the Hk2-Vdac1 mitochondrial axis","volume":"225","author":"Cai","year":"2024","journal-title":"Free Radic Biol Med"},{"issue":"7","key":"10.1016\/j.trsl.2026.05.004_bib0109","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1111\/iej.14057","article-title":"STING inhibition alleviates bone resorption in apical periodontitis","volume":"57","author":"Mao","year":"2024","journal-title":"Int Endod J"},{"issue":"9","key":"10.1016\/j.trsl.2026.05.004_bib0110","doi-asserted-by":"crossref","first-page":"6593","DOI":"10.1021\/acs.jmedchem.1c01948","article-title":"Novel CRBN-recruiting proteolysis-targeting chimeras as degraders of stimulator of interferon genes with In vivo anti-inflammatory efficacy","volume":"65","author":"Liu","year":"2022","journal-title":"J Med Chem"},{"issue":"1","key":"10.1016\/j.trsl.2026.05.004_bib0111","doi-asserted-by":"crossref","first-page":"4584","DOI":"10.1038\/s41467-024-48922-w","article-title":"Small molecule induced STING degradation facilitated by the HECT ligase HERC4","volume":"15","author":"Mutlu","year":"2024","journal-title":"Nat Commun"},{"issue":"6","key":"10.1016\/j.trsl.2026.05.004_bib0112","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1039\/D3CC05127G","article-title":"Covalent PROTAC design method based on a sulfonyl pyridone probe","volume":"60","author":"Luo","year":"2024","journal-title":"Chem Commun"},{"key":"10.1016\/j.trsl.2026.05.004_bib0113","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116883","article-title":"Discovery of novel nitrofuran PROTAC-like compounds as dual inhibitors and degraders targeting STING","volume":"279","author":"Xue","year":"2024","journal-title":"Eur J Med Chem"},{"issue":"1","key":"10.1016\/j.trsl.2026.05.004_bib0114","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/s41392-023-01468-7","article-title":"Evolving cognition of the JAK-STAT signaling pathway: autoimmune disorders and cancer","volume":"8","author":"Xue","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.trsl.2026.05.004_bib0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2022.109095","article-title":"Advance in bone destruction participated by JAK\/STAT in rheumatoid arthritis and therapeutic effect of JAK\/STAT inhibitors","volume":"111","author":"Hu","year":"2022","journal-title":"Int Immunopharmacol"},{"issue":"7","key":"10.1016\/j.trsl.2026.05.004_bib0116","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1002\/art.41666","article-title":"Characterization and function of tumor necrosis factor and interleukin-6\u2013Induced osteoclasts in rheumatoid arthritis","volume":"73","author":"Yokota","year":"2021","journal-title":"Arthritis Rheumatol"},{"issue":"530","key":"10.1016\/j.trsl.2026.05.004_bib0117","doi-asserted-by":"crossref","first-page":"eaay4447","DOI":"10.1126\/scitranslmed.aay4447","article-title":"JAK inhibition increases bone mass in steady-state conditions and ameliorates pathological bone loss by stimulating osteoblast function","volume":"12","author":"Adam","year":"2020","journal-title":"Sci Transl Med"},{"issue":"5","key":"10.1016\/j.trsl.2026.05.004_bib0118","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.ccell.2019.10.002","article-title":"A potent and selective small-molecule degrader of STAT3 achieves complete tumor regression In vivo","volume":"36","author":"Bai","year":"2019","journal-title":"Cancer Cell"},{"issue":"24","key":"10.1016\/j.trsl.2026.05.004_bib0119","doi-asserted-by":"crossref","first-page":"11280","DOI":"10.1021\/acs.jmedchem.9b01530","article-title":"Structure-based discovery of SD-36 as a potent, selective, and efficacious PROTAC degrader of STAT3 protein","volume":"62","author":"Zhou","year":"2019","journal-title":"J Med Chem"},{"issue":"5","key":"10.1016\/j.trsl.2026.05.004_bib0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2020.115326","article-title":"Hi-JAK-ing the ubiquitin system: the design and physicochemical optimisation of JAK PROTACs","volume":"28","author":"Shah","year":"2020","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.trsl.2026.05.004_bib0121","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2024.129838","article-title":"Discovery of a potent and selective JAK1-targeting PROTAC degrader with anti-tumor activities","volume":"109","author":"Zhang","year":"2024","journal-title":"Bioorg Med Chem Lett"},{"issue":"23","key":"10.1016\/j.trsl.2026.05.004_bib0122","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1182\/blood.2020006846","article-title":"Degradation of Janus kinases in CRLF2-rearranged acute lymphoblastic leukemia","volume":"138","author":"Chang","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.trsl.2026.05.004_bib0123","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.116167","article-title":"JAK1\/JAK2 degraders based on PROTAC for topical treatment of atopic dermatitis","volume":"171","author":"Wu","year":"2024","journal-title":"Biomed Pharmacother"},{"issue":"9","key":"10.1016\/j.trsl.2026.05.004_bib0124","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1021\/acs.jnatprod.5b00233","article-title":"Harpagoside inhibits RANKL-induced osteoclastogenesis via syk-btk-PLC\u03b32-Ca(2+) signaling pathway and prevents inflammation-mediated bone loss","volume":"78","author":"Kim","year":"2015","journal-title":"J Nat Prod"},{"key":"10.1016\/j.trsl.2026.05.004_bib0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115664","article-title":"Discovery of Ibrutinib-based BTK PROTACs with in vivo anti-inflammatory efficacy by inhibiting NF-\u03bab activation","volume":"259","author":"Huang","year":"2023","journal-title":"Eur J Med Chem"},{"issue":"4","key":"10.1016\/j.trsl.2026.05.004_bib0126","doi-asserted-by":"crossref","first-page":"2438","DOI":"10.1021\/acs.jmedchem.3c01414","article-title":"Discovery of novel potent and fast BTK PROTACs for the treatment of osteoclasts-related inflammatory diseases","volume":"67","author":"Huang","year":"2024","journal-title":"J Med Chem"},{"key":"10.1016\/j.trsl.2026.05.004_bib0127","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2024.111525","article-title":"Extracellular CIRP induces abnormal activation of fibroblast-like synoviocytes from patients with RA via the TLR4-mediated HDAC3 pathways","volume":"128","author":"Yao","year":"2024","journal-title":"Int Immunopharmacol"},{"issue":"1","key":"10.1016\/j.trsl.2026.05.004_bib0128","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1136\/annrheumdis-2015-209064","article-title":"Histone deacetylase 3 regulates the inflammatory gene expression programme of rheumatoid arthritis fibroblast-like synoviocytes","volume":"76","author":"Angiolilli","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.trsl.2026.05.004_bib0129","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1177\/0022034519885088","article-title":"HDAC3 Regulates gingival fibroblast inflammatory responses in periodontitis","volume":"99","author":"Lagosz","year":"2020","journal-title":"J Dent Res"},{"issue":"10","key":"10.1016\/j.trsl.2026.05.004_bib0130","doi-asserted-by":"crossref","first-page":"2862","DOI":"10.7150\/thno.23547","article-title":"MicroRNA-193b-3p regulates chondrogenesis and chondrocyte metabolism by targeting HDAC3","volume":"8","author":"Meng","year":"2018","journal-title":"Theranostics"},{"key":"10.1016\/j.trsl.2026.05.004_bib0131","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/9972805","article-title":"BMSC-derived exosomes ameliorate osteoarthritis by inhibiting pyroptosis of cartilage via delivering miR-326 targeting HDAC3 and STAT1\/\/NF-\u03bab p65 to chondrocytes","volume":"2021","author":"Xu","year":"2021","journal-title":"Mediat Inflamm"},{"issue":"68","key":"10.1016\/j.trsl.2026.05.004_bib0132","doi-asserted-by":"crossref","first-page":"9866","DOI":"10.1039\/D0CC03243C","article-title":"Discovery of histone deacetylase 3 (HDAC3)-specific PROTACs","volume":"56","author":"Xiao","year":"2020","journal-title":"Chem Commun"},{"issue":"11","key":"10.1016\/j.trsl.2026.05.004_bib0133","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1016\/j.chembiol.2023.07.010","article-title":"HDAC3 and HDAC8 PROTAC dual degrader reveals roles of histone acetylation in gene regulation","volume":"30","author":"Xiao","year":"2023","journal-title":"Cell Chem Biol"},{"key":"10.1016\/j.trsl.2026.05.004_bib0134","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112800","article-title":"Induced protein degradation of histone deacetylases 3 (HDAC3) by proteolysis targeting chimera (PROTAC)","volume":"208","author":"Cao","year":"2020","journal-title":"Eur J Med Chem"},{"issue":"42","key":"10.1016\/j.trsl.2026.05.004_bib0135","article-title":"Histone deacetylase 3-directed PROTACs have anti-inflammatory potential by blocking polarization of M0-like into M1-like macrophages","volume":"62","author":"Zhao","year":"2023","journal-title":"Angew Chem Int Engl"},{"issue":"17","key":"10.1016\/j.trsl.2026.05.004_bib0136","doi-asserted-by":"crossref","DOI":"10.1096\/fj.202400642R","article-title":"SHP2 ablation mitigates osteoarthritic cartilage degeneration by promoting chondrocyte anabolism through SOX9","volume":"38","author":"Wang","year":"2024","journal-title":"FASEB J"},{"key":"10.1016\/j.trsl.2026.05.004_bib0137","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.freeradbiomed.2025.02.042","article-title":"A Keap1-recruiting BRD4 degrader offers a single-molecular polypharmacology approach for the treatment of metabolic dysfunction-associated steatohepatitis","volume":"232","author":"Zhang","year":"2025","journal-title":"Free Radic Biol Med"},{"issue":"12","key":"10.1016\/j.trsl.2026.05.004_bib0138","doi-asserted-by":"crossref","first-page":"3158","DOI":"10.3390\/biomedicines10123158","article-title":"Lipid nanoparticles and liposomes for bone diseases treatment","volume":"10","author":"Burdu\u0219el","year":"2022","journal-title":"Biomedicines"},{"issue":"10","key":"10.1016\/j.trsl.2026.05.004_bib0139","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1016\/j.drudis.2020.07.013","article-title":"Optimising proteolysis-targeting chimeras (PROTACs) for oral drug delivery: a drug metabolism and pharmacokinetics perspective","volume":"25","author":"Pike","year":"2020","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.trsl.2026.05.004_bib0140","article-title":"Immune and stem cell-mediated bactericidal amplification and bone remodeling for infection clearance and osteointegration","volume":"38","author":"Li","year":"2026","journal-title":"Adv Mater"},{"issue":"32","key":"10.1016\/j.trsl.2026.05.004_bib0141","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202401833","article-title":"Mussel-derived and bioclickable peptide mimic for enhanced interfacial osseointegration via synergistic immunomodulation and vascularized bone regeneration","volume":"11","author":"Zhou","year":"2024","journal-title":"Adv Sci"},{"issue":"7","key":"10.1016\/j.trsl.2026.05.004_bib0142","doi-asserted-by":"crossref","first-page":"2716","DOI":"10.1039\/C9BM00201D","article-title":"Glucosamine sulphate-loaded distearoyl phosphocholine liposomes for osteoarthritis treatment: combination of sustained drug release and improved lubrication","volume":"7","author":"Ji","year":"2019","journal-title":"Biomater Sci"},{"key":"10.1016\/j.trsl.2026.05.004_bib0143","first-page":"37","article-title":"Synergistically targeting synovium STING pathway for rheumatoid arthritis treatment","volume":"24","author":"Shen","year":"2023","journal-title":"Bioact Mater"},{"issue":"9","key":"10.1016\/j.trsl.2026.05.004_bib0144","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.3390\/pharmaceutics15092339","article-title":"Enhancing osteoporosis treatment through targeted nanoparticle delivery of risedronate: in vivo evaluation and bioavailability enhancement","volume":"15","author":"Saifi","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.trsl.2026.05.004_bib0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2024.108725","article-title":"Powering up targeted protein degradation through active and passive tumour-targeting strategies: current and future scopes","volume":"263","author":"Venkatesan","year":"2024","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.trsl.2026.05.004_bib0146","doi-asserted-by":"crossref","DOI":"10.1016\/j.colsurfb.2020.110795","article-title":"Targeted degradation of anaplastic lymphoma kinase by gold nanoparticle-based multi-headed proteolysis targeting chimeras","volume":"188","author":"Wang","year":"2020","journal-title":"Colloids Surf B Biointerfaces"},{"key":"10.1016\/j.trsl.2026.05.004_bib0147","doi-asserted-by":"crossref","DOI":"10.1016\/j.cej.2022.137039","article-title":"2D-PROTACs with augmented protein degradation for super-resolution photothermal optical coherence tomography guided momentary multimodal therapy","volume":"446","author":"Liu","year":"2022","journal-title":"Chem Eng J"},{"issue":"2","key":"10.1016\/j.trsl.2026.05.004_bib0148","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1038\/s41565-024-01801-3","article-title":"Targeted protein degradation via cellular trafficking of nanoparticles","volume":"20","author":"Liu","year":"2025","journal-title":"Nat Nanotechnol"},{"key":"10.1016\/j.trsl.2026.05.004_bib0149","first-page":"207","article-title":"A bone-targeted engineered exosome platform delivering siRNA to treat osteoporosis","volume":"10","author":"Cui","year":"2022","journal-title":"Bioact Mater"},{"key":"10.1016\/j.trsl.2026.05.004_bib0150","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.jconrel.2021.11.019","article-title":"M2-type exosomes nanoparticles for rheumatoid arthritis therapy via macrophage re-polarization","volume":"341","author":"Li","year":"2022","journal-title":"J Control Release"},{"issue":"16","key":"10.1016\/j.trsl.2026.05.004_bib0151","article-title":"Chondrocyte-targeted delivery system of Sortase A-engineered extracellular vesicles silencing MMP13 for osteoarthritis therapy","volume":"13","author":"Yan","year":"2024","journal-title":"Adv Heal Mater"},{"issue":"20","key":"10.1016\/j.trsl.2026.05.004_bib0152","doi-asserted-by":"crossref","first-page":"9571","DOI":"10.1021\/acs.nanolett.3c03148","article-title":"Targeted protein degradation mediated by genetically engineered lysosome-targeting exosomes","volume":"23","author":"Wang","year":"2023","journal-title":"Nano Lett"},{"issue":"8","key":"10.1016\/j.trsl.2026.05.004_bib0153","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.3390\/pharmaceutics16081070","article-title":"Unlocking the potential of Camel milk-derived exosomes as novel delivery systems: enhanced bioavailability of ARV-825 PROTAC for cancer therapy","volume":"16","author":"Nathani","year":"2024","journal-title":"Pharmaceutics"},{"issue":"4","key":"10.1016\/j.trsl.2026.05.004_bib0154","doi-asserted-by":"crossref","first-page":"501","DOI":"10.3390\/pharmaceutics17040501","article-title":"PROTAC delivery strategies for overcoming physicochemical properties and physiological barriers in targeted protein degradation","volume":"17","author":"Syahputra","year":"2025","journal-title":"Pharmaceutics"},{"issue":"9","key":"10.1016\/j.trsl.2026.05.004_bib0155","doi-asserted-by":"crossref","first-page":"2727","DOI":"10.1016\/j.matt.2021.05.019","article-title":"Nanoscale materials-based platforms for the treatment of bone-related diseases","volume":"4","author":"Zhang","year":"2021","journal-title":"Matter"},{"issue":"6","key":"10.1016\/j.trsl.2026.05.004_bib0156","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202511840","article-title":"A Pseudo-Mytilus Edulis Foot protein-based hydrogel adhesive with osteo-vascular-immune coupling effects for osteoporotic bone-implant integration","volume":"38","author":"Wang","year":"2026","journal-title":"Adv Mater"},{"issue":"6","key":"10.1016\/j.trsl.2026.05.004_bib0157","doi-asserted-by":"crossref","first-page":"3262","DOI":"10.1021\/acsbiomaterials.5c00597","article-title":"Hydrogel-based strategies for managing rheumatoid arthritis: from sustained drug release to cell-based therapies","volume":"11","author":"Back","year":"2025","journal-title":"ACS Biomater Sci Eng"},{"issue":"13","key":"10.1016\/j.trsl.2026.05.004_bib0158","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.3390\/polym13132106","article-title":"Differentiating Co-delivery of bisphosphonate and simvastatin by self-healing hyaluronan hydrogel formed by orthogonal \u201cclicks\u201d: an In-vitro assessment","volume":"13","author":"Ossipov","year":"2021","journal-title":"Polymers"},{"issue":"11","key":"10.1016\/j.trsl.2026.05.004_bib0159","doi-asserted-by":"crossref","first-page":"885","DOI":"10.3390\/gels9110885","article-title":"Advanced hydrogel-based strategies for enhanced bone and cartilage regeneration: a comprehensive review","volume":"9","author":"De Leon-Oliva","year":"2023","journal-title":"Gels"},{"issue":"4","key":"10.1016\/j.trsl.2026.05.004_bib0160","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1021\/acsabm.4c01968","article-title":"Injectable hydrogel technologies for bone disease treatment","volume":"8","author":"Salama","year":"2025","journal-title":"ACS Appl Bio Mater"},{"issue":"14","key":"10.1016\/j.trsl.2026.05.004_bib0161","doi-asserted-by":"crossref","first-page":"6857","DOI":"10.7150\/thno.112782","article-title":"Bioinspired nano-micron hydrogel microspheres for periodontitis therapy through synergistic multi-targeted remodeling of microenvironment","volume":"15","author":"Zhou","year":"2025","journal-title":"Theranostics"},{"issue":"12","key":"10.1016\/j.trsl.2026.05.004_bib0162","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202210787","article-title":"A physiologically responsive nanocomposite hydrogel for treatment of head and neck squamous cell carcinoma via proteolysis-targeting Chimeras enhanced immunotherapy","volume":"35","author":"Wu","year":"2023","journal-title":"Adv Mater"},{"issue":"13","key":"10.1016\/j.trsl.2026.05.004_bib0163","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202306248","article-title":"A nucleic acid-based LYTAC plus platform to simultaneously mediate disease-driven protein downregulation","volume":"11","author":"Huang","year":"2024","journal-title":"Adv Sci"},{"key":"10.1016\/j.trsl.2026.05.004_bib0164","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1038\/s41587-024-02494-8","article-title":"Engineered platelets as targeted protein degraders and application to breast cancer models","volume":"43","author":"Chen","year":"2025","journal-title":"Nat Biotechnol"},{"issue":"9","key":"10.1016\/j.trsl.2026.05.004_bib0165","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.4065\/83.9.1032","article-title":"Bisphosphonates: mechanism of action and role in clinical practice","volume":"83","author":"Drake","year":"2008","journal-title":"Mayo Clin Proc"},{"issue":"5","key":"10.1016\/j.trsl.2026.05.004_bib0166","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1021\/bc7002132","article-title":"Osteotropic peptide that differentiates functional domains of the skeleton","volume":"18","author":"Wang","year":"2007","journal-title":"Bioconjug Chem"},{"issue":"17","key":"10.1016\/j.trsl.2026.05.004_bib0167","doi-asserted-by":"crossref","first-page":"6864","DOI":"10.1021\/acs.nanolett.4c06279","article-title":"Smartphone-manipulated mild-temperature photothermal control of the TfR-LYTAC platform for tumor treatment","volume":"25","author":"Shi","year":"2025","journal-title":"Nano Lett"},{"issue":"10","key":"10.1016\/j.trsl.2026.05.004_bib0168","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/s41568-021-00365-x","article-title":"Advancing targeted protein degradation for cancer therapy","volume":"21","author":"Dale","year":"2021","journal-title":"Nat Rev Cancer"},{"issue":"9","key":"10.1016\/j.trsl.2026.05.004_bib0169","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1038\/nrm2745","article-title":"Lysosome biogenesis and lysosomal membrane proteins: trafficking meets function","volume":"10","author":"Saftig","year":"2009","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"1","key":"10.1016\/j.trsl.2026.05.004_bib0170","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1080\/03008200390181753","article-title":"The role of RANKL (TRANCE\/TNFSF11), a tumor necrosis factor family member, in skeletal development: effects of gene knockout and transgenic rescue","volume":"44","author":"Odgren","year":"2003","journal-title":"Connect Tissue Res"},{"issue":"24","key":"10.1016\/j.trsl.2026.05.004_bib0171","doi-asserted-by":"crossref","first-page":"6275","DOI":"10.3390\/ijms20246275","article-title":"NF-\u03bab signaling regulates physiological and pathological chondrogenesis","volume":"20","author":"Jimi","year":"2019","journal-title":"Int J Mol Sci"}],"container-title":["Translational Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S193152442600099X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S193152442600099X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T10:23:40Z","timestamp":1783160620000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S193152442600099X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":171,"alternative-id":["S193152442600099X"],"URL":"https:\/\/doi.org\/10.1016\/j.trsl.2026.05.004","relation":{},"ISSN":["1931-5244"],"issn-type":[{"value":"1931-5244","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeted protein degradation in inflammatory bone diseases: Mechanistic basis and therapeutic opportunities","name":"articletitle","label":"Article Title"},{"value":"Translational Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.trsl.2026.05.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}